“This multicenter real-world study suggests that first-line tislelizumab combined with platinum-etoposide chemotherapy provides encouraging efficacy with an acceptable safety profile in patients with ...

T-cell lymphomas represent a heterogeneous and often aggressive group of hematologic malignancies for which the optimal consolidation strategy, autologous or allogeneic hematopoietic stem cell ...

The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.

Ottensmeier C, Delord JP, Lalanne A, et al. A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized phase I trial. Nat ...

The second clinical scenario considers a 72-year-old patient with multiple myeloma who is triple-class exposed and has experienced disease progression after a BCMA-directed T-cell-engaging therapy.